{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:11:11Z","timestamp":1789193471841,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patients with D-IBS alone. Eighty-five patients with CP\/CPPS (45 with subtype IIIa and 40 with IIIb) plus D-IBS according to the Rome III criteria and an aged-matched control-group of patients with D-IBS alone (n = 75) received rifaximin and VSL#3. The primary endpoints were the response rates of IBS and CP\/CPPS symptoms, assessed respectively through Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) and The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and performed at the start of therapy (V0) and three months after (V3). In IIIa prostatitis patients, the total NIH-CPSI scores significantly (p &lt; 0.05) decreased from a baseline mean value of 21.2 to 14.5 at V3 , as did all subscales, and in the IIIb the total NIH-CPSI score also significantly decreased (from 17.4 to 15.1). Patients with IBS alone showed no significant differences in NIH-CPSI score. At V3, significantly greater improvement in the IBS-SSS and responder rate were found in IIIa patients. Our results were explained through a better individual response at V3 in IIIa prostatitis of urinary and gastrointestinal symptoms, while mean leukocyte counts on expressed prostate secretion (EPS) after prostate massage significantly lowered only in IIIa cases.<\/jats:p>","DOI":"10.3390\/nu9111208","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T12:39:20Z","timestamp":1509712760000},"page":"1208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-2942","authenticated-orcid":false,"given":"Enzo","family":"Vicari","sequence":"first","affiliation":[{"name":"Section of Endocrinology, Andrology and Internal Medicine, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Salemi","sequence":"additional","affiliation":[{"name":"IRCCS Oasi Institute for Research on Mental Retardation and Brain Aging, Via Conte Ruggiero 73, 94018 Troina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sidoti","sequence":"additional","affiliation":[{"name":"UOSD Medicina Interna Ambulatorio Andrologia & Endocrinologia ARNAS\u2014Garibaldi, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Malaguarnera","sequence":"additional","affiliation":[{"name":"Research Center \u201cThe Great Senescence\u201d, University of Catania, 95100 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Castiglione","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Andrology and Internal Medicine, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Landis, J.R., Williams, D.A., Lucia, M.S., Clauw, D.J., Naliboff, B.D., Robinson, N.A., van Bokhoven, A., Sutcliffe, S., Schaeffer, A.J., and Rodriguez, L.V. (2014). MAPP Research Network Study Group. The MAPP research network: Design, patient characterization and operations. BMC Urol., 14.","DOI":"10.1186\/1471-2490-14-58"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0090-4295(98)00034-X","article-title":"Prevalence of a physician-assigned diagnosis of prostatitis: The Olmstead County study of urinary symptoms and health status among men","volume":"51","author":"Roberts","year":"1998","journal-title":"Urology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0022-5347(05)65301-3","article-title":"Prevalence and correlates of prostatitis in the health professionals follow-up study cohort","volume":"167","author":"Collins","year":"2002","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5056\/jnm14165","article-title":"Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World","volume":"21","author":"Oshima","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12144","DOI":"10.3748\/wjg.v20.i34.12144","article-title":"Irritable bowel syndrome: A clinical review","volume":"20","author":"Soares","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vicari, E., La Vignera, S., Arcoria, D., Condorelli, R., Vicari, L.O., Castiglione, R., Mangiameli, A., and Calogero, A.E. (2011). High frequency of chronic bacterial and non-inflammatory prostatitis in infertile patients with prostatitis syndrome plus irritable bowel syndrome. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018647"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11136-005-1317-1","article-title":"Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)","volume":"15","author":"Propert","year":"2006","journal-title":"Qual. Life Res."},{"key":"ref_8","first-page":"338","article-title":"Investigation of chronic prostatitis and altered bowel habits","volume":"8","author":"Li","year":"2002","journal-title":"Zhonghua Nan Ke Xue"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.juro.2009.07.036","article-title":"National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain Evidence for overlap between urological and nonurological unexplained clinical conditions","volume":"182","author":"Afari","year":"2009","journal-title":"Urology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_11","first-page":"865","article-title":"Microbiology synergism between tear substitutes and symbiotic treatment of patients with irritable bowel syndrome","volume":"32","author":"Chisari","year":"2016","journal-title":"Acta Med. Mediterr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/00365520310004209","article-title":"An irritable bowel syndrome-specific symptom questionnaire: Development and validation","volume":"38","author":"Wiklund","year":"2003","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Roalfe, A.K., Roberts, L.M., and Wilson, S. (2008). Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol., 8.","DOI":"10.1186\/1471-230X-8-30"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)68562-X","article-title":"The NIH Chronic Prostatitis Symptom Index (NIH-CPSI): Development and validation of a new outcomes measure","volume":"162","author":"Litwin","year":"1999","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: Potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2005.03.008","article-title":"A model of neural cross-talk and irritation in the pelvis: Implications for the overlap of chronic pelvic pain disorders","volume":"128","author":"Pezzone","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4103\/1008-682X.131064","article-title":"Chronic bacterial prostatitis and irritable bowel syndrome: Effectiveness of treatment with rifaximin followed by the probiotic VSL#3","volume":"16","author":"Vicari","year":"2014","journal-title":"Asian J. Androl."},{"key":"ref_22","first-page":"866","article-title":"The physiopathology of lipoprotein (a)","volume":"2","author":"Galvano","year":"2010","journal-title":"Front. Biosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5056\/jnm.2012.18.1.70","article-title":"Gender role in irritable bowel syndrome: A comparison of irritable bowel syndrome module (ROME III) between male and female patients","volume":"18","author":"Anbardan","year":"2012","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40477-017-0252-7","article-title":"Ultrasound as point of care in management of polytrauma and its complication","volume":"20","author":"Latteri","year":"2017","journal-title":"J. Ultrasound"},{"key":"ref_25","first-page":"249","article-title":"Risk factors for ocular surface disorders in patients with type 2 diabetes","volume":"30","author":"Chisari","year":"2014","journal-title":"Acta Medica Mediterr."},{"key":"ref_26","first-page":"2510","article-title":"Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis, C. treated with pegylated interferon \u03b1 and ribavirin","volume":"7","author":"Malaguarnera","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Pennisi, M., Bertino, G., Gagliano, C., Malaguarnera, M., Bella, R., Borz\u00ec, A.M., Madeddu, R., Drago, F., and Malaguarnera, G. (2017). Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-\u03b1-2b and Ribavirin Reduces Sleep Disturbance. Nutrients, 9.","DOI":"10.3390\/nu9080897"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1186\/1471-2482-13-S2-S50","article-title":"Localized and systemic bacterial infections in necrotizing pancreatitis submitted to surgical necrosectomy or percutaneous drainage of necrotic secretions","volume":"13","author":"Cacopardo","year":"2013","journal-title":"BMC Surg."},{"key":"ref_29","unstructured":"Grabe, M., Bjerklund-Johansen, T.E., Botto, H., \u00c7ek, M., Naber, K.G., Pickard, R.S., Tenke, P., Wagenlehner, F., and Wullt, B. (2012). Guidelines on Urological Infections, European Association of Urology."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0022-5347(05)66344-6","article-title":"Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatitis\/chronic pelvic pain syndrome: A prospective multicenter clinical trial","volume":"165","author":"Nickel","year":"2001","journal-title":"J. Urol."},{"key":"ref_31","first-page":"492","article-title":"Bacteriologic localization patterns in bacterial prostatitis and urethritis","volume":"5","author":"Meares","year":"1968","journal-title":"Investig. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-5347(05)64572-7","article-title":"Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study","volume":"168","author":"Schaeffer","year":"2002","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11894-005-0018-9","article-title":"Symptom overlap and comorbidity of irritable bowel syndrome with other conditions","volume":"7","author":"Frissora","year":"2005","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2002.32392","article-title":"Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?","volume":"122","author":"Whitehead","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ajg.2014.202","article-title":"Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5056\/jnm15071","article-title":"Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?","volume":"21","author":"Mazurak","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000019784","article-title":"The role of antibiotics in the treatment of chronic prostatitis: A consensus statement","volume":"34","author":"Gruneberg","year":"1998","journal-title":"Eur. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1097\/01.ju.0000055549.95490.3c","article-title":"Long-term results of multimodal therapy for chronic prostatitis\/chronic pelvic pain syndrome","volume":"169","author":"Shoskes","year":"2003","journal-title":"J. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"G171","DOI":"10.1152\/ajpgi.00048.2015","article-title":"Homeostasis of the gut barrier and potential biomarkers","volume":"312","author":"Wells","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17474124.2017.1343664","article-title":"From clinical uncertainties to precision medicine: The emerging role of the gut barrier and microbiome in small bowel functional diseases","volume":"11","author":"Marlicz","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4111\/kju.2008.49.1.72","article-title":"Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha-blocker combination therapy for patients with inflammatory chronic prostatitis\/chronic pelvic pain syndrome","volume":"49","author":"Youn","year":"2008","journal-title":"Korean J. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/03091902.2010.539770","article-title":"Insights into \u2018Fermentonomics\u2019: Evaluation of volatile organic compounds (VOCs) in human disease using an Electronic \u2018e\u2019 Nose","volume":"35","author":"Arasaradnam","year":"2011","journal-title":"J. Med. Eng. Technol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2164\/jandrol.111.014654","article-title":"Male accessory gland infection frequency in infertile patients with chronic microbial prostatitis and irritable bowel syndrome: Transrectal ultrasound examination helps to understand the links","volume":"33","author":"Vicari","year":"2012","journal-title":"J. Androl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2008.42","article-title":"Clinical phenotyping in chronic prostatitis\/chronic pelvic pain syndrome and interstitial cystitis: A management strategy for urologic chronic pelvic pain syndromes","volume":"12","author":"Shoskes","year":"2009","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.juro.2010.08.025","article-title":"Use of the UPOINT chronic prostatitis\/chronic pelvic pain syndrome classification in European patient cohorts: Sexual function domain improves correlations","volume":"184","author":"Magri","year":"2010","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2468-1253(16)30022-X","article-title":"Functional gastrointestinal disorders: What\u2019s new for Rome IV?","volume":"1","author":"Drossman","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/9\/11\/1208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:47:58Z","timestamp":1760208478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/9\/11\/1208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["nu9111208"],"URL":"https:\/\/doi.org\/10.3390\/nu9111208","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,3]]}}}